Results 181 to 190 of about 187,608 (218)

Illuminating point‐of‐care diagnostics with aggregation‐induced emission biosensors

FlexMat, EarlyView.
This review highlights the application of aggregation‐induced emission luminogens (AIEgens) in point‐of‐care (POC) diagnostics for disease biomarker detection. It systematically examines a range of biosensing platforms, including lateral flow immunoassays, microfluidic chips, and electrochemiluminescence sensors, alongside their utility in detecting ...
Danni Hu, Yubing Hu, Dong Wang, Ben Zhong Tang   +3 more
wiley   +1 more source

The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study. [PDF]

Nat Commun
Lee V, Sachidanand AS, Rodriguez C, Wang J, Onners B, Qi H, Parkinson R, McPhaul T, Durham J, Ding D, Hacker-Prietz A, Narang AK, Le DT, De Jesus A, Pishvaian M, Christenson E, Thompson ED, Anders RA, Osipov A, Weiss M, Burns W, Burkhart R, Lafaro K, He J, Wolfgang CL, Sugar E, Herman JM, Jaffee EM, Wang H, Laheru DA, Zheng L.   +30 more
europepmc   +1 more source

Effectiveness of a Primary‐Care‐Centered Integrated Care Intervention for Stratified Cardiovascular Risk Control in China: Study Protocol for a Pragmatic Cluster Randomized Controlled Trial

Health Care Science, EarlyView.
This study developed a multifaceted intervention to strengthen primary care for cardiovascular risk management by leveraging both primary care and county hospitals in rural China. The purpose of this multicentre, cluster‐randomized controlled trial is to evaluate the effectiveness of intervention on the prevention of cardiovascular risks among patients
Weijia Lu, Xinxin Xia, Ziming Wang, Yaoyun Zhang, Yiting Lin, Wuxiang Xie, Jin Xu   +6 more
wiley   +1 more source

Advances on cancer vaccine trials registered in China and the USA in 2014-2024. [PDF]

Front Oncol
Shi W, Chen Z, Yu Q, Zhang L.
europepmc   +1 more source

Cancer vaccine trial evaluations: immunobridging and potential immunological endpoints. [PDF]

Immunother Adv
Hussain A, Moxley-Wyles B, Bryan M, Gordon-Weeks A, Al-Obaidi I, Sandhu C, Lee L.   +6 more
europepmc   +1 more source

Development of the rationale of a personalized cancer vaccine based on the in situ vaccine effect of radiotherapy: a mechanistic study of the POLARSTAR trial. [PDF]

Cancer Immunol Immunother
Pang K, Sun P, Liu X, Yang D, Zhao P, Huang Y, Cao S, Gao Y, Chen G, Yu H, Duan L, Yang Y, Zhang Z.   +12 more
europepmc   +1 more source

Health System Resilience and Afghan Refugee Health in Pakistan: An Exploratory Study of Challenges and Pathways to Inclusion

The International Journal of Health Planning and Management, EarlyView.
ABSTRACT Pakistan has hosted Afghan refugees for more than four decades, in one of the world's most protracted displacements of people. Afghan refugees receive health services through United Nations High Commissioner for Refugees (UNHCR) and non‐governmental organisation (NGO) supported programmes alongside public sector facilities at every tier.
Zahid Ali Memon, Asma Ummad, Amina Olabi, Natasha Palmer, Sophie Witter   +4 more
wiley   +1 more source

Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells. [PDF]

Acta Biomater
Zhou J, Liu Y, Xu W, Bhatta R, Han J, Baskaran D, Devmal S, Leal C, Wang H.   +8 more
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source